Trial Profile
Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 22 Apr 2014 Status changed from active, no longer recruiting to completed.
- 08 May 2012 Planned end date (Mar 2013) added as reported by University Hospital Medical Information Network - Japan.
- 08 May 2012 Status changed from not stated to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.